+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Remicade Market Size, Share & Trends Analysis Report by Type (Branded, Biosimilar), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Remicade Market Size, Share & Trends Analysis Report by Type (Branded, Biosimilar), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Remicade Market Size, Share & Trends Analysis Report by Type (Branded, Biosimilar), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098088
Description Jump to:
The Remicade Market was valued at USD 3.04 billion in 2024, and is projected to reach USD 2.62 billion by 2030, rising at a CAGR of -2.28%. Despite a gradual decline in brand dominance, the Remicade (infliximab) market continues to show sustained demand, driven by the global burden of autoimmune diseases such as Crohn’s disease and rheumatoid arthritis. Remicade has remained a widely prescribed biologic for these conditions. However, the market is undergoing significant change due to the increasing entry and acceptance of biosimilars, supported by evolving regulatory policies and healthcare cost-effective strategies.

The decline in market share is closely tied to the broader availability of biosimilar infliximab options. With patents expiring in key regions, biosimilars have become more accessible, particularly in countries with public healthcare systems seeking cost savings. This shift is encouraging broader patient access to treatment while intensifying price competition, challenging the position of the original product. Still, Remicade’s extensive clinical history and physician familiarity support its use, especially in complex cases.

Opportunities for market growth remain, especially in regions where biologic use is still expanding. In markets across Asia, Latin America, and parts of the Middle East and Africa, improvements in healthcare infrastructure and rising awareness of inflammatory diseases are driving increased demand for both originator biologics and biosimilars. Moreover, ongoing clinical research and new infliximab formulations, including subcutaneous delivery, contribute to the evolving therapeutic landscape.

Pharmaceutical companies involved in the Remicade industry, including Janssen, Celltrion, and Pfizer, are responding to these shifts with strategies such as regional licensing deals, post-approval manufacturing partnerships, and investment in real-world evidence. Biosimilar developers also leverage differentiation tactics, including high-concentration formulations and co-marketing agreements, to strengthen market entry.

Remicade Market Report Highlights

  • Based on type, the branded segment led the market with the largest revenue share of 52.8% in 2024. This dominance is attributable to strong physician trust, established clinical data, slower biosimilar adoption in certain markets, and patient trust in the brand.
  • Based on indication, the rheumatoid arthritis segment led the market with the largest revenue share of 20.8% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024, due to their direct access to specialized treatments, strong physician recommendations, and higher patient volumes for complex autoimmune conditions, making them the preferred distribution channel for Remicade (infliximab).
  • In March 2024, Celltrion announced plans to introduce its original drug, Zymfentra, to the U.S. market. The launch of Zymfentra, a treatment for autoimmune diseases, marks a significant step in Celltrion's strategy to expand its portfolio beyond biosimilars. This move reflects the company's broader strategy to diversify its offerings and leverage its expertise in biologic drug development for new therapeutic areas.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Indication
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Remicade Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Remicade Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Branded
4.4.1. Branded Market, 2018-2030 (USD Million)
4.5. Biosimilar
4.5.1. Biosimilar Market, 2018-2030 (USD Million)
Chapter 5. Remicade Market: Indication Business Analysis
5.1. Indication Market Share, 2024 & 2030
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
5.4. Rheumatoid Arthritis
5.4.1. Rheumatoid Arthritis Market, 2018-2030 (USD Million)
5.5. Psoriatic Arthritis
5.5.1. Psoriatic Arthritis Market, 2018-2030 (USD Million)
5.6. Crohn’s Disease
5.6.1. Crohn’s Disease Market, 2018-2030 (USD Million)
5.7. Ulcerative Colitis
5.7.1. Ulcerative Colitis Market, 2018-2030 (USD Million)
5.8. Ankylosing Spondylitis
5.8.1. Ankylosing Spondylitis Market, 2018-2030 (USD Million)
5.9. Others
5.9.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Remicade Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 7. Remicade Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. North America Remicade Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. Canada Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Remicade Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Janssen Pharmaceuticals (Johnson & Johnson);
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Type Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Celltrion
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Type Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Type Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Type Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Novartis AG
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Type Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Teva Pharmaceutical Industries Ltd
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Type Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Pfizer Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Type Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Samsung Bioepis
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Type Benchmarking
8.5.8.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Remicade market, by region, 2018-2030 (USD Million)
Table 4. Global Remicade market, by type, 2018-2030 (USD Million)
Table 5. Global Remicade market, by indication, 2018-2030 (USD Million)
Table 6. Global Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 7. North America Remicade market, by country, 2018-2030 (USD Million)
Table 8. North America Remicade market, by type, 2018-2030 (USD Million)
Table 9. North America Remicade market, by indication, 2018-2030 (USD Million)
Table 10. North America Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 11. U.S. Remicade market, by type, 2018-2030 (USD Million)
Table 12. U.S. Remicade market, by indication, 2018-2030 (USD Million)
Table 13. U.S. Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 14. Canada Remicade market, by type, 2018-2030 (USD Million)
Table 15. Canada Remicade market, by indication, 2018-2030 (USD Million)
Table 16. Canada Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 17. Mexico Remicade market, by type, 2018-2030 (USD Million)
Table 18. Mexico Remicade market, by indication, 2018-2030 (USD Million)
Table 19. Mexico Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 20. Europe Remicade market, by country, 2018-2030 (USD Million)
Table 21. Europe Remicade market, by type, 2018-2030 (USD Million)
Table 22. Europe Remicade market, by indication, 2018-2030 (USD Million)
Table 23. Europe Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 24. UK Remicade market, by type, 2018-2030 (USD Million)
Table 25. UK Remicade market, by indication, 2018-2030 (USD Million)
Table 26. UK Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 27. Germany Remicade market, by type, 2018-2030 (USD Million)
Table 28. Germany Remicade market, by indication, 2018-2030 (USD Million)
Table 29. Germany Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 30. France Remicade market, by type, 2018-2030 (USD Million)
Table 31. France Remicade market, by indication, 2018-2030 (USD Million)
Table 32. France Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 33. Italy Remicade market, by type, 2018-2030 (USD Million)
Table 34. Italy Remicade market, by indication, 2018-2030 (USD Million)
Table 35. Italy Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 36. Spain Remicade market, by type, 2018-2030 (USD Million)
Table 37. Spain Remicade market, by indication, 2018-2030 (USD Million)
Table 38. Spain Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 39. Norway Remicade market, by type, 2018-2030 (USD Million)
Table 40. Norway Remicade market, by indication, 2018-2030 (USD Million)
Table 41. Norway Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 42. Denmark Remicade market, by type, 2018-2030 (USD Million)
Table 43. Denmark Remicade market, by indication, 2018-2030 (USD Million)
Table 44. Denmark Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 45. Sweden Remicade market, by type, 2018-2030 (USD Million)
Table 46. Sweden Remicade market, by indication, 2018-2030 (USD Million)
Table 47. Sweden Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 48. Asia Pacific Remicade market, by country, 2018-2030 (USD Million)
Table 49. Asia Pacific Remicade market, by type, 2018-2030 (USD Million)
Table 50. Asia Pacific Remicade market, by indication, 2018-2030 (USD Million)
Table 51. Asia Pacific Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 52. Japan Remicade market, by type, 2018-2030 (USD Million)
Table 53. Japan Remicade market, by indication, 2018-2030 (USD Million)
Table 54. Japan Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 55. China Remicade market, by type, 2018-2030 (USD Million)
Table 56. China Remicade market, by indication, 2018-2030 (USD Million)
Table 57. China Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 58. India Remicade market, by type, 2018-2030 (USD Million)
Table 59. India Remicade market, by indication, 2018-2030 (USD Million)
Table 60. India Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 61. Australia Remicade market, by type, 2018-2030 (USD Million)
Table 62. Australia Remicade market, by indication, 2018-2030 (USD Million)
Table 63. Australia Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 64. South Korea Remicade market, by type, 2018-2030 (USD Million)
Table 65. South Korea Remicade market, by indication, 2018-2030 (USD Million)
Table 66. South Korea Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 67. Thailand Remicade market, by type, 2018-2030 (USD Million)
Table 68. Thailand Remicade market, by indication, 2018-2030 (USD Million)
Table 69. Thailand Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 70. Latin America Remicade market, by country, 2018-2030 (USD Million)
Table 71. Latin America Remicade market, by type, 2018-2030 (USD Million)
Table 72. Latin America Remicade market, by indication, 2018-2030 (USD Million)
Table 73. Latin America Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 74. Brazil Remicade market, by type, 2018-2030 (USD Million)
Table 75. Brazil Remicade market, by indication, 2018-2030 (USD Million)
Table 76. Brazil Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 77. Argentina Remicade market, by type, 2018-2030 (USD Million)
Table 78. Argentina Remicade market, by indication, 2018-2030 (USD Million)
Table 79. Argentina Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 80. Middle East & Africa Remicade market, by country, 2018-2030 (USD Million)
Table 81. Middle East & Africa Remicade market, by type, 2018-2030 (USD Million)
Table 82. Middle East & Africa Remicade market, by indication, 2018-2030 (USD Million)
Table 83. Middle East & Africa Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 84. South Africa Remicade market, by type, 2018-2030 (USD Million)
Table 85. South Africa Remicade market, by indication, 2018-2030 (USD Million)
Table 86. South Africa Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 87. Saudi Arabia Remicade market, by type, 2018-2030 (USD Million)
Table 88. Saudi Arabia Remicade market, by indication, 2018-2030 (USD Million)
Table 89. Saudi Arabia Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 90. UAE Remicade market, by type, 2018-2030 (USD Million)
Table 91. UAE Remicade market, by indication, 2018-2030 (USD Million)
Table 92. UAE Remicade market, by distribution channel, 2018-2030 (USD Million)
Table 93. Kuwait Remicade market, by type, 2018-2030 (USD Million)
Table 94. Kuwait Remicade market, by indication, 2018-2030 (USD Million)
Table 95. Kuwait Remicade market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Remicade market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and indication outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Remicade market dynamics
Figure 12 Remicade market: Porter’s five forces analysis
Figure 13 Remicade market: PESTLE analysis
Figure 14 Type market, 2018-2030 (USD Million)
Figure 15 Branded market, 2018-2030 (USD Million)
Figure 16 Biosimilar market, 2018-2030 (USD Million)
Figure 17 Indication market, 2018-2030 (USD Million)
Figure 18 Rheumatoid Arthritis market, 2018-2030 (USD Million)
Figure 19 Psoriatic Arthritis market, 2018-2030 (USD Million)
Figure 20 Crohn’s Diseases market, 2018-2030 (USD Million)
Figure 21 Ulcerative Colitis market, 2018-2030 (USD Million)
Figure 22 Ankylosing Spondylitis market, 2018-2030 (USD Million)
Figure 23 Others market, 2018-2030 (USD Million)
Figure 24 Distribution Channel market, 2018-2030 (USD Million)
Figure 25 Hospital Pharmacies market, 2018-2030 (USD Million)
Figure 26 Retail Pharmacies market, 2018-2030 (USD Million)
Figure 27 Online Pharmacies market, 2018-2030 (USD Million)
Figure 28 Remicade market revenue, by region
Figure 29 Regional marketplace: Key takeaways
Figure 30 Regional marketplace: Key takeaways
Figure 31 North America Remicade market, 2018-2030 (USD Million)
Figure 32 US country dynamics
Figure 33 US Remicade market, 2018-2030 (USD Million)
Figure 34 Canada country dynamics
Figure 35 Canada Remicade market, 2018-2030 (USD Million)
Figure 36 Mexico country dynamics
Figure 37 Mexico Remicade market, 2018-2030 (USD Million)
Figure 38 Europe Remicade market, 2018-2030 (USD Million)
Figure 39 UK country dynamics
Figure 40 UK Remicade market, 2018-2030 (USD Million)
Figure 41 Germany country dynamics
Figure 42 Germany Remicade market, 2018-2030 (USD Million)
Figure 43 France country dynamics
Figure 44 France Remicade market, 2018-2030 (USD Million)
Figure 45 Italy country dynamics
Figure 46 Italy Remicade market, 2018-2030 (USD Million)
Figure 47 Spain country dynamics
Figure 48 Spain Remicade market, 2018-2030 (USD Million)
Figure 49 Norway country dynamics
Figure 50 Norway Remicade market, 2018-2030 (USD Million)
Figure 51 Sweden country dynamics
Figure 52 Sweden Remicade market, 2018-2030 (USD Million)
Figure 53 Denmark country dynamics
Figure 54 Denmark Remicade market, 2018-2030 (USD Million)
Figure 55 Asia Pacific Remicade market, 2018-2030 (USD Million)
Figure 56 Japan country dynamics
Figure 57 Japan Remicade market, 2018-2030 (USD Million)
Figure 58 China country dynamics
Figure 59 China Remicade market, 2018-2030 (USD Million)
Figure 60 India country dynamics
Figure 61 India Remicade market, 2018-2030 (USD Million)
Figure 62 Australia country dynamics
Figure 63 Australia Remicade market, 2018-2030 (USD Million)
Figure 64 South Korea country dynamics
Figure 65 South Korea Remicade market, 2018-2030 (USD Million)
Figure 66 Thailand country dynamics
Figure 67 Thailand Remicade market, 2018-2030 (USD Million)
Figure 68 Latin America Remicade market, 2018-2030 (USD Million)
Figure 69 Brazil country dynamics
Figure 70 Brazil Remicade market, 2018-2030 (USD Million)
Figure 71 Argentina country dynamics
Figure 72 Argentina Remicade market, 2018-2030 (USD Million)
Figure 73 MEA Remicade market, 2018-2030 (USD Million)
Figure 74 South Africa country dynamics
Figure 75 South Africa Remicade market, 2018-2030 (USD Million)
Figure 76 Saudi Arabia country dynamics
Figure 77 Saudi Arabia Remicade market, 2018-2030 (USD Million)
Figure 78 UAE country dynamics
Figure 79 UAE Remicade market, 2018-2030 (USD Million)
Figure 80 Kuwait country dynamics
Figure 81 Kuwait Remicade market, 2018-2030 (USD Million)
Figure 82 Company categorization
Figure 83 Company market position analysis
Figure 84 Strategic framework

Companies Mentioned

The major companies featured in this Remicade market report include:
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Celltrion
  • Pfizer Inc.
  • Samsung Bioepis.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Remicade Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Remicade Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
REMICADE Drug Insight and Market Forecast - 2032 - Product Image

REMICADE Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • 30 Pages
  • Global
From
Remicade Biosimilar Market Report 2025 - Product Image

Remicade Biosimilar Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Remicade Biosimilar Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Remicade Biosimilar Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 108 Pages
  • Global
From
Investigation Report on China's Infliximab Market 2022-2031 - Product Image

Investigation Report on China's Infliximab Market 2022-2031

  • Report
  • 40 Pages
  • China
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.